SFG
ADPT icon

Strive Financial Group’s Adaptive Biotechnologies ADPT Stock Holding History

Strive Financial Group’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.1K Sell
2,430
-750
-24% -$11.5K 0.02% 268
2026
Q1 		$44K Hold
3,180
– – 0.02% 237
2025
Q4 		$51.6K Buy
+3,180
New +$51.9K 0.03% 216

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Strive Financial Group's ADPT Position: Q2 2026 in Review

Strive Financial Group reduced its Adaptive Biotechnologies (ADPT) stake by 24% in Q2 2026, selling an estimated $11.5K and leaving 2,430 shares worth $52.1K. The position accounts for 0.02% of the portfolio, ranked #268.

Strive Financial Group first reported a position in ADPT in Q4 2025 and has held it in 3 quarters since. 299 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Strive Financial Group held 2,430 shares of Adaptive Biotechnologies worth $52.1K as of Q2 2026.
  • Strive Financial Group sold 750 Adaptive Biotechnologies shares in Q2 2026, an estimated $11.5K.
  • Adaptive Biotechnologies made up 0.02% of Strive Financial Group's portfolio in Q2 2026, its #268 holding.
  • Strive Financial Group first reported a position in Adaptive Biotechnologies in Q4 2025 and has held it in 3 quarters since.
  • 299 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Strive Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.